

# Dermatology Enrollment Form (A-N)

Phone: 602-971-6950 / 877-971-3001

Fax: 877-552-5698



An AleraCare Company **AleraCare**  
A Healthcare Solutions Company

*Patients must bring an original prescription to the pharmacy. Faxed prescriptions will only be accepted from a prescribing practitioner.*

Prescriber Information			
Prescriber Name:			<input type="radio"/> MD <input type="radio"/> DO <input type="radio"/> NP <input type="radio"/> PA <input type="radio"/> NPI:
Office Contact:		Practice Name / Collaborating MD:	
Address:			City:
State:	Zip:	Phone:	Fax:

Patient Information   PLEASE SEND COPY OF INSURANCE CARD							
Patient's Name:		Last 4 Digits of SS#:	DOB: / /	Sex: <input type="radio"/> M <input type="radio"/> F	Weight:	Height:	Diabetic: <input type="radio"/> Y <input type="radio"/> N
Address:			City:	State:	Zip:	Allergies:	
Home Phone:		Work Or Cell:	HIPAA Contact:	Emergency #:	Interpreter Needed? <input type="radio"/> Y <input type="radio"/> N		

Insurance Information			
Primary Insurance:		Policy ID:	Group #:
Policyholder Name:		Policyholder DOB:	BIN: PCN:

Clinical Information   PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES							
<b>ICD-10/Diagnosis Code:</b> <input type="radio"/> Psoriasis Vulgaris (L40.0) <input type="radio"/> Other Psoriasis (L40.8) <input type="radio"/> Psoriasis unspecified (L40.9) <input type="radio"/> Psoriatic Arthritis (L40.5) <input type="radio"/> Hidradenitis Suppurativa (L73.2) <input type="radio"/> Chronic Urticaria (L50.8)							
<input type="radio"/> Atopic Dermatitis (L20.9) <input type="radio"/> Basal cell carcinoma (C44.____)		TB/PDD Test Given? <input type="radio"/> Y <input type="radio"/> N	Date of Neg. Test: / /	HBV Positive? <input type="radio"/> Y <input type="radio"/> N	If yes, patient currently treated? <input type="radio"/> Y <input type="radio"/> N		
Prior Treatment? <input type="radio"/> Y <input type="radio"/> N (Provide Information Below)		BSA affected (%):	Affected Areas: <input type="radio"/> Palms <input type="radio"/> Soles <input type="radio"/> Head <input type="radio"/> Neck <input type="radio"/> Genitalia <input type="radio"/> Other:				
Prior Therapy		Reason for Discontinuation of Therapy			Approx. Start Date	Approx. End Date	
Comorbidities:		Concomitant Medications:			Allergies: <input type="radio"/> NKDA <input type="radio"/> Other:		

Prescription Information			
Medication	Quantity/Dose	Sig	Refills
<input type="radio"/> <b>CIMZIA®</b> <input type="radio"/> PFS <input type="radio"/> Vials	<input type="radio"/> 1 starter kit (6x200mg/mL)	<input type="radio"/> <b>Starter Dose:</b> Inject 400 mg SQ at weeks 0, 2 and 4	<b>No Refills</b>
	<input type="radio"/> 1 carton (2x200mg/mL) <input type="radio"/> 2 cartons (4x200mg/mL)	<b>Maintenance Dose:</b> <input type="radio"/> Inject 400mg SQ every 4 weeks <input type="radio"/> Inject 200mg SQ every 2 weeks <input type="radio"/> Inject 400mg SQ every other week (plaque psoriasis only) <input type="radio"/> Inject 200mg SQ every other week	
<input type="radio"/> <b>COSENTYX®</b> <input type="radio"/> PFS <input type="radio"/> Sensoready® Pen	<input type="radio"/> 4 cartons (8x150mg/mL) <input type="radio"/> 4 cartons (4x150mg/mL)	<input type="radio"/> <b>Starter Dose:</b> Inject 300 mg SQ at weeks 0, 1, 2, and 3 <input type="radio"/> <b>Starter Dose:</b> Inject 150 mg SQ at weeks 0, 1, 2, and 3	<b>No Refills</b>
	<input type="radio"/> 1 carton (2x150mg/mL) <input type="radio"/> 1 carton (1x150mg/mL)	<input type="radio"/> <b>Maintenance Dose:</b> Inject 300 mg SQ every 4 weeks beginning on Day 29 <input type="radio"/> <b>Maintenance Dose:</b> Inject 150 mg SQ every 4 weeks beginning on Day 29	
<input type="radio"/> <b>DUPIXENT®</b> <input type="radio"/> PFS (with needle shield)	<input type="radio"/> 1 carton (2x200mg/114mL) <input type="radio"/> 1 carton (2x300mg/2mL)	<b>Starter Dose:</b> <input type="radio"/> <b>Adolescents weighing less than 60kg:</b> Inject 400mg SQ at week 0. Begin maintenance dose at week 2 <input type="radio"/> <b>Adolescents weighing ≥60kg and adults:</b> Inject 600mg SQ at week 0. Begin maintenance dose at week 2	<b>No Refills</b>
	<input type="radio"/> 1 carton (2x200mg/114mL) <input type="radio"/> 1 carton (2x300mg/2mL)	<b>Maintenance Dose:</b> <input type="radio"/> <b>Adolescents weighing less than 60kg:</b> Inject 200mg SQ every 2 weeks <input type="radio"/> <b>Adolescents weighing ≥ 60kg and adults:</b> Inject 300mg SQ every 2 weeks	
<input type="radio"/> <b>ENBREL®</b> <input type="radio"/> Mini <input type="radio"/> PFS <input type="radio"/> SureClick® <input type="radio"/> Vial	<input type="radio"/> 6 cartons (24x50mg/mL)	<input type="radio"/> <b>Starter Dose:</b> Inject 50 mg SQ twice a week (72-96 hours apart) x 3 months	<b>No Refills</b>
	<input type="radio"/> 1 carton (4x50mg/mL) <input type="radio"/> <b>PFS:</b> 1 carton (4x25mg/0.5mL) <input type="radio"/> <b>Vial:</b> 1 carton (4x25mg/mL)	<input type="radio"/> <b>Maintenance Dose:</b> Inject 50 mg SQ every week <input type="radio"/> <b>Pediatric Dose:</b> < 63 kg (138 lbs) Inject _____ mg (0.8mg/kg) SQ once a week <input type="radio"/> <b>Pediatric Dose:</b> > 63 kg (138 lbs or more) Inject 50 mg SQ once a week	
<input type="radio"/> <b>HUMIRA®</b> (Plaque Psoriasis) <input type="radio"/> Pens <input type="radio"/> PFS	<b>Pens Only:</b> <input type="radio"/> Starter Kit (4x40mg/0.8mL) <input type="radio"/> Citrate-Free Starter Kit (1x80mg/0.8mL, 2x40mg/0.4mL)	<input type="radio"/> <b>Starter Dose:</b> Inject 80 mg SQ Day 1, then 40mg on day 8, then 1 pen every 2 weeks	<b>No Refills</b>
	<input type="radio"/> 1 carton (2x40mg/0.8mL) <input type="radio"/> <b>Citrate Free:</b> 1 carton (2x40mg/0.4mL)	<input type="radio"/> <b>Maintenance Dose:</b> Inject 40 mg SQ every 2 weeks	
<input type="radio"/> <b>HUMIRA®</b> (Hidradenitis Suppurativa) <input type="radio"/> Pens <input type="radio"/> PFS	<b>Pens Only:</b> <input type="radio"/> Starter Kit (6x40mg/0.8mL) <input type="radio"/> Citrate-Free Starter Kit (3x80mg/0.8mL)	<input type="radio"/> <b>Starter Dose:</b> <input type="radio"/> <b>Adolescents weighing 30-59kg:</b> Inject 80mg SQ on day 1, 40mg on day 8 and 40mg on day 22 <input type="radio"/> <b>Adolescents weighing ≥ 60kg and adults:</b> Inject 160mg SQ day 1 (or 80mg SQ on day 1 and day 2); then 80mg on day 15; then begin maintenance dosing on day 29	<b>No Refills</b>
	<input type="radio"/> 2 cartons (4x40mg/0.8mL) <input type="radio"/> <b>Citrate Free:</b> 2 cartons (4x40mg/0.4mL)	<b>Maintenance Dose:</b> <input type="radio"/> <b>Adolescents weighing 30-59kg:</b> Inject 40mg SQ every other week <input type="radio"/> <b>Adolescents weighing ≥ 60kg and adults:</b> Inject 40mg SQ every week	
<input type="radio"/> <b>ILUMYA™</b>	<input type="radio"/> 1 carton (1x100mg/mL PFS)	<input type="radio"/> <b>Starter Dose:</b> Inject 100mg SQ at weeks 0 and 4 <input type="radio"/> <b>Maintenance Dose:</b> Inject 100mg SQ every 12 weeks	<b>No Refills</b>

Injection Training		
<input type="radio"/> Patient received pens and injection training	<input type="radio"/> Physician's office to provide injection training	<input type="radio"/> VascoRx to coordinate injection training or infusion
By signing this form and utilizing our services, you are authorizing VascoRx and its employees to serve as your prior authorization agent in dealing with medical and prescription insurance companies and copay assistance foundation.		
Prescriber Signature: Substitution Permitted	Date	Prescriber Signature: Dispense as Written
		Date

Important Notice: This information is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute or copy the information contained in this correspondence. Please notify the sender immediately if you received this document in error and then destroy this document immediately.